Cytosorbents (HQE) Stock Statistics & Valuation Metrics
Total Valuation
Cytosorbents has a market cap or net worth of EUR 11.55M. The enterprise value is EUR 49.06M.
- Market Cap
- EUR 11.55M
- Enterprise Value
- EUR 49.06M
Share Statistics
Cytosorbents has 3,151,101 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 3,151,101
- Owned by Insiders
- 23.46%
- Owned by Institutions
- 36.63%
Financial Efficiency
Cytosorbents’s return on equity (ROE) is -1.39 and return on invested capital (ROIC) is -38.77%.
- Return on Equity (ROE)
- -1.39
- Return on Assets (ROA)
- -0.19
- Return on Invested Capital (ROIC)
- -38.77%
- Return on Capital Employed (ROCE)
- -0.41
- Revenue Per Employee
- 287.31K
- Profits Per Employee
- -63.55K
- Employee Count
- 129
- Asset Turnover
- 0.84
- Inventory Turnover
- 2.00
Valuation Ratios
The current PE Ratio of Cytosorbents is -0.79. Cytosorbents’s PEG ratio is 0.01.
- PE Ratio
- -0.79
- PS Ratio
- 0.38
- PB Ratio
- -18.98
- Price to FCF
- -1.37
- Price to Operating Cash Flow
- -1.38
- PEG Ratio
- 0.01
Income Statement
In the last 12 months, Cytosorbents had revenue of 37.06M and earned -8.20M in profits. Earnings per share was -2.60.
- Revenue
- 37.06M
- Gross Profit
- 26.49M
- Operating Income
- -14.24M
- Pretax Income
- -8.60M
- Net Income
- -8.20M
- EBITDA
- -4.36M
- Earnings Per Share (EPS)
- -2.60
Cash Flow
In the last 12 months, operating cash flow was -10.31M and capital expenditures -115,883, giving a free cash flow of -10.42M billion.
- Operating Cash Flow
- -10.31M
- Free Cash Flow
- -10.42M
- Free Cash Flow per Share
- -3.32
Dividends & Yields
Cytosorbents pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -72.87%
- Earnings Yield
- -127.75%
Stock Price Statistics
- Beta
- 0.76
- 52-Week Price Change
- -59.03%
- 50-Day Moving Average
- 5.41
- 200-Day Moving Average
- 7.82
- Relative Strength Index (RSI)
- 47.48
- Average Volume (3m)
- ―
Important Dates
Cytosorbents upcoming earnings date is Nov 12, 2026, After Close (Not Confirmed).
- Last Earnings Date
- Aug 06, 2026
- Next Earnings Date
- Nov 12, 2026
- Ex-Dividend Date
- ―
Financial Position
Cytosorbents as a current ratio of 2.13, with Debt / Equity ratio of 493.16%
- Current Ratio
- 2.13
- Quick Ratio
- 1.58
- Debt to Market Cap
- 0.42
- Net Debt to EBITDA
- -5.25
- Interest Coverage Ratio
- -5.45
Taxes
In the past 12 months, Cytosorbents has paid -401.00K in taxes.
- Income Tax
- -401.00K
- Effective Tax Rate
- 0.05
Enterprise Valuation
Cytosorbents EV to EBITDA ratio is -2.60, with an EV/FCF ratio of -3.48.
- EV to Sales
- 0.97
- EV to EBITDA
- -2.60
- EV to Free Cash Flow
- -3.48
- EV to Operating Cash Flow
- -3.51
Balance Sheet
Cytosorbents has EUR 4.41M in cash and marketable securities with EUR 26.33M in debt, giving a net cash position of -EUR 21.92M billion.
- Cash & Marketable Securities
- EUR 4.41M
- Total Debt
- EUR 26.33M
- Net Cash
- -EUR 21.92M
- Net Cash Per Share
- -EUR 6.96
- Tangible Book Value Per Share
- -EUR 1.15
Margins
Gross margin is 71.61%, with operating margin of -33.37%, and net profit margin of -48.94%.
- Gross Margin
- 71.61%
- Operating Margin
- -33.37%
- Pretax Margin
- -50.02%
- Net Profit Margin
- -48.94%
- EBITDA Margin
- -37.51%
- EBIT Margin
- -41.64%
Analyst Forecast
The average price target for Cytosorbents is EUR 10.90, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- EUR 10.90
- Price Target Upside
- 101.81% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 2
- Revenue Growth Forecast
- 1.50%
- EPS Growth Forecast
- -46.53%
